A role for spleen monocytes in post-ischemic brain inflammation and injury by Bao, Yi et al.
SHORT REPORT Open Access
A role for spleen monocytes in post-ischemic
brain inflammation and injury
Yi Bao
1, Eunhee Kim
1, Sangram Bhosle
1, Heeral Mehta
1, Sunghee Cho
1,2*
Abstract
Although infiltration of peripheral monocytes/macrophages is implicated in stroke pathology, in vivo data regarding
the deployment of monocytes and their mobilization to the infarct area is scarce. Recent literature showed that
mouse monocytes exhibit two distinct populations that represent pro-inflammatory (Ly-6C
hi/CCR2+) and anti-
inflammatory (Ly-6C
low/CCR2-) subsets and that spleen is a major source for monocyte deployment upon injury. By
reducing post-ischemic infection with antibacterial moxifloxacin (MFX) treatment, the present study investigates the
effect of the treatment on Ly-6C and CCR2 expression in the spleen following ischemia and the extent to which
the effect is associated with attenuation of post-ischemic inflammation and injury. Mice subjected to a middle cer-
ebral artery occlusion (MCAO) showed a significant reduction in their spleen weights compared to sham animals.
Compared to vehicle controls, splenocytes obtained from daily MFX-treated mice 7 days after ischemia exhibited
significantly reduced mean Ly-6C expression within pro-inflammatory subsets, whereas the distribution of pro- and
anti-inflammatory subsets was not different between the treatment groups. Additionally, MFX treatment signifi-
cantly reduced CCR2 expression in the spleen tissue and in the post-ischemic brain and attenuated infarct size. The
study suggests a potential contributing role of spleen monocytes in post-ischemic inflammation and injury. The
influence of peripheral inflammatory status on the primary injury in the CNS further implies that the attenuation of
post-stroke infection may be beneficial in mitigating stroke-induced brain injury.
Findings
Ischemia-reperfusion causes inflammation that attracts
monocyte/macrophage cells to infarct [1-3]. Monocytes
are circulating antigen-presenting leukocytes that play
an important role in inflammation, T-cell differentiation,
phagocytosis, and innate immunity [4,5]. It has been
shown that circulating and spleen monocytes are similar
in their morphology, phagocytic capability, and gene
expression profiles [6]. The study also identified the
spleen as a monocyte reservoir and their numbers in the
spleen are several folds higher than in circulation [6]. In
addition, the number of monocytes that migrate to the
infarct area after a myocardial infarction well exceeds
the number in circulation under homeostatic conditions
[4]. These studies suggest a potential role of the spleen
in deploying monocytes upon cerebral ischemia.
Human and mouse monocytes exhibit distinct subsets
that are reminiscent of macrophage phenotypes [5,7,8].
In mice, the subset that expresses a high level of the hema-
topoietic cell differentiation antigen Ly-6C (Ly-6C
hi)a l s o
expresses the G-protein linked membrane protein, CCR2.
The Ly-6C
hi/CCR2+ monocyte subset is specifically
recruited to an injury site by monocyte chemoattractant
protein-1 (MCP-1), which is produced by the inflamed tis-
sue, and become classically activated M1 macrophages. In
contrast, the Ly-6C
low monocyte subset expresses CX3CR1,
a receptor for the chemokine CX3CL1 (fractalkine), but is
devoid of CCR2 expression. This anti-inflammatory Ly-
6C
low/CCR2-/CX3CR1+ subset is recruited to normal tissue
and develops into resident M2 macrophages that function
in host defense and repair after injury [9,10]. Recruitment
of the pro-inflammatory Ly-6C
hi/CCR2+ subset to inflam-
matory sites is believed to be CCR2-dependent, since
monocytes from CCR2-null mice do not traffic as efficiently
into a myocardial infarct as CCR2+ monocytes [6]. Further-
more, CCR2-null mice were protective against cerebral
inflammation following ischemia [11], suggesting that
CCR2 is a contributing factor for stroke-induced injury.
Studies suggest a potential influence of peripheral
inflammatory status on primary injury. Fever and systemic
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suffering from stroke and are associated with increased
mortality and poorer outcome [12,13]. Treatment with
antibacterial agents such as moxifloxacin (MFX) and min-
ocycline was shown to reduce infarct in experimental ani-
mal models of stroke [14,15]. In addition, MFX treatment
also reduced peripheral infection in patients who have suf-
fered an ischemic stroke and in animal models of stroke
[16]. The present study investigates whether improving
peripheral infection by treatment with MFX shifts spleen
monocytes to a less pro-inflammatory state and if the
effect is associated with attenuation of post-ischemic
inflammation and injury. Here, we report a potential influ-
ence of peripheral inflammatory status on stroke-induced
inflammation and injury.
All experimental procedures on animals were
approved by the Institutional Animal Care and Use
Committee of Weill Medical College of Cornell Univer-
sity. C57BL/6 male mice obtained from Jackson Labora-
tory (Bar Harbor, ME) were subjected to a 40 min
middle cerebral artery occlusion (MCAO) as described
previously [17,18]. The cerebral blood flow (CBF) in the
center of the ischemic territory was monitored by laser-
Doppler flowmetry (Periflux System 5010; Perimed, Jar-
falla, Sweden). Moxifloxacin (MFX; Bayer, Wayne, NJ)
solution (10 mg/ml) was prepared in a mixture of saline
a n d1m o l / LH C l( 1 0 : 1 )a n da d j u s t e dt op H7w i t h
NaOH. Mice were treated with either vehicle or MFX
solution (100 mg/kg) immediately after reperfusion,
then once a day for 7 days following MCAO and sacri-
ficed 7 days after ischemia. Sham-operated mice served
as controls. Brains were removed, frozen, and sectioned
(thickness, 20 μm) in a cryostat as previously described
[17,18]. Brain sections were collected serially at 600 μm
intervals, and stained with Cresyl Violet. Infarct volume
was determined using Axiovision (Zeiss, Germany) and
the contribution due to swelling was corrected.
The distribution of monocyte subsets and expression
o fL y - 6 Cw e r ea n a l y z e db yf l o wc y t o m e t r y / F A C S
according to a published method [6]. After removal of
RBC using a lysis buffer (Sigma-Aldrich, St. Louis, MO),
single splenocyte suspension was incubated with a cock-
tail of phycoerythrin (PE)-conjugated antibodies (BD
Biosciences, San Jose, California) against T cells
(CD90.2-PE, Clone 53-2.1), B cells (CD45R/B220-PE,
Clone RA3-6B2), NK cells (CD49b/Pan-NK cells-PE,
Clone DX5,; NK1.1-PE, Clone PK136), granulocytes (Ly-
6G-PE, Clone 1A8), allophycocyanin (APC)-conjugated
antibody against myeloid cells including monocytes/
macrophages (CD11b-APC, Clone M1/70), and fluores-
cein isothiocyanate (FITC)-conjugated antibody to
monocyte subsets (Ly-6C-F I T C ,C l o n eA L - 2 1 ) .A f t e r
washing with Dulbecco’s phosphate buffer saline (DPBS,
VWR, West Chester, PA), 100,000 cells were analyzed
by FACS. The selected gate (low PE/high APC which
were identified as monocytes) was further analyzed for
Ly-6C-FITC.
The procedures for RNA isolation and real time
reverse transcriptase (RT)-PCR for gene expression were
previously described [17]. Relative mRNA levels were
quantified with real-time quantitative RT-PCR (qPCR)
using fluorescent TaqMan technology. PCR primers spe-
cific for CCR2, MCP-1 and b-actin (internal control)
were obtained as TaqMan pre-developed optimized
assay reagents for gene expression (Applied Biosystems,
Foster City, CA). The PCR reaction was performed
using FastStart Universal Probe Master (Roche), accord-
ing to the manufacturer’s instructions. Reactions were
performed in 20 μl total volumes and incubated at 95°C
f o r1 0m i n ,f o l l o w e db y4 5c y c l e so f1 5sa t9 5 ° Ca n d
1 min at 60°C. The results were analyzed by 7500 Fast
Real-Time PCR System software. For CCR2 protein
levels, spleen was homogenized in radioimmunoprecipi-
tation assay buffer (RIPA buffer, Sigma-Aldrich) with
freshly added protease inhibitors (Sigma-Aldrich) and
centrifuged at 10,000 rpm for 10 min at 4°C. The proto-
col for SDS-PAGE and western blot were described pre-
viously [17]. After blocking the membrane for 1 h, anti-
CCR2 monoclonal antibody (1:1000, ab32144, Abcam,
Cambridge, MA) and anti-a-tubulin antibody as internal
control (1:1000, T6199, Sigma-Aldrich) were added, fol-
lowed by IRDye 680 Goat anti-rabbit IgG and IRDye
800 Donkey anti-mouse IgG for CCR2 and for a-tubulin
respectively (1:10,000, LI-COR). The bands were visua-
lized using the Odyssey Imaging System (LI-COR).
To investigate involvement of the spleen in stroke
pathology, spleen weights were determined after
MCAO. Ischemia caused significant reductions in spleen
weight at 3 and 7 days post-ischemia with a larger
reduction at 7 days (Figure 1A). Since body and spleen
weights are significantly correlated in normal mice (R
2 =
0.85, p < 0.001, n = 13), we consider the possibility that
the reduced spleen weights are due to body weight loss
following stroke. Normalization of spleen weight by
body weight still revealed significant weight reductions
in the spleen (Figure 1B), indicating a potential involve-
ment of spleen in stroke pathology.
Spleen monocytes were shown to resemble circulating
monocytes in their morphology, phagocytic capability and
transcriptome [6]. To reflect peripheral inflammatory
state, we treated mice with vehicle or MFX after MCAO
and analyzed the spleen weights and monocyte subsets in
the spleen. Compared to pre-ischemic spleen weight (76.2
± 3.6 mg, n = 9), stroke caused similar reductions in
spleen weight between vehicle- and MFX-treated mice at
7 days post-ischemia (49.86 ± 7.92 mg vs 47.95 ± 5.66 mg,
ns, n = 10-12). The lack of difference in weight at this
time point may be due to immediate deployment of spleen
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source for monocytes [6]. Further FACS analyses in the
selected gate for monocytes (Figure 2A, R1) revealed no
differences in subset distribution between the treatment
groups. However, MFX-treated mice showed reduction in
mean Ly-6C expression within pro-inflammatory Ly-6C
hi
subset (Figure 2). The reduced mean Ly-6C expression in
MFX-treated mice was also associated with attenuated
CCR2 gene and protein expression (Figure 3A &3B). The
findings are consistent with other reports showing
increased Ly-6C expression in response to pro-inflamma-
tory stimuli [19,20] and reduced expression of cytokines
and Ly-6C in CCR2-null mice [6,21,22]. Collectively, our
findings indicate that MFX treatment following stroke
shifts the spleen toward a less inflammatory state.
We further investigated whether the MFX treatment
influences the expression of MCP-1 and CCR2, a pri-
mary inflammatory axis and injury in the ischemic
brain. Stroke increased MCP-1 mRNA levels in the
infarct similarly in both groups (Figure 4A). Interest-
ingly, MFX treated group showed a significant reduction
in CCR2 mRNA levels in the post-ischemic brain, sug-
gesting either less CCR2+ cell infiltration or reduced
CCR2 expression in infiltrated cells to the injury site
(Figure 4B). This was accompanied by a modest but sig-
nificant reduction in infarct size (Figure 4C).
Despite a neurocentric view of stroke-induced brain
injury, infiltration of peripheral monocytes/macrophages
into the infarct territory indicates the influence of these
immune cells in developing brain injury [23-26]. Although
controversial, approximately 10-20% of infiltrated cells
express markers for monocytes/macrophages [27,28].
With reported peripheral studies showing that prolonged
systemic inflammation following stroke exacerbates brain
injury and MFX treatment reduces the peripheral infection
and improves ischemic outcome [14,16], the present study
addresses the biological events that underlie the peripheral
influence on stroke injury. Although recruited monocytes
are thought to arise from systemic circulation and bone
marrow, the unexpected finding that identifies the spleen
as an immediate reservoir to deploy a large quantity of
monocytes upon injury [6], argues for a novel role of
spleen monocytes in stroke pathology.
The MFX-induced shift to less inflammatory status in
the periphery was accompanied by reduced CCR2
expression in the post-ischemic brain (Figure 4B). CCR2
is a chemokine receptor for MCP-1, and the CCR2/
MCP-1 axis plays a critical role in a host of inflammatory
conditions [11,29,30]. Although it has been shown that
other CNS cells, such as neurons and microglia, also
express CCR2 in pathological conditions [31], it is
believed that the major source of CCR2 in the post-
ischemic brain is from the periphery. The reduced CCR2
expression, thereby attenuating post-ischemic inflamma-
tion in MFX-treated mice, may be due to reduced traf-
ficking of monocytes to the injury site and/or attenuated
CCR2 expression among recruited cells. Since we found
that MFX treatment reduces Ly-6C expression in the
pro-inflammatory subset (Figure 2), these findings sup-
port the view that a shift of spleen Ly-6C
hi subset to a
less inflammatory phenotype may account for the
reduced CCR2 expression in MFX-treated mice.
Consistent with literatures showing that MFX improves
ischemic outcome and reduces peripheral infection both
in animal models and patients [14,16,32,33], we also
observed that MFX treatment resulted in a moderate but
significant reduction in injury size. The MFX-treated mice
also exhibited a smaller interanimal variability in injury
Figure 1 Effect of ischemia on spleen weight. A, Quantification of spleen weight before (pre) and after (post) ischemia. B, Quantification of
spleen weight expressed ratios of spleen to body weight. Pre, control mice, n = 9; 3d-post, 3 days after MCAO, n = 6; 7d-post, 7 days after
MCAO, n = 10. Values were expressed as mean ± SEM. ** p < 0.01 and *** p < 0.001 vs pre.
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Page 3 of 6Figure 2 Effect of MFX on monocyte subset distribution and Ly-6C expression in the spleen following stroke. A, The monocyte subsets
were identified by selecting the gate (APC-CD11b
hi and PE-Lin
low in left panel) and further separated by FITC-Ly-6C
hi/low (right panel). PE-Lin: PE-
conjugated CD90/B220/CD49b/NK1.1/Ly-6G; APC-CD11b: APC-conjugated CD11b; FITC-Ly-6C: FITC-conjugated Ly-6C. B & C, Quantification of
spleen monocyte subsets by their distribution (B) and mean Ly-6C intensities within each subset (C). n = 5/group. * p < 0.05 vs Veh.
Figure 3 Effect of MFX on CCR2 expression in the spleen following stroke.C C R 2m R N A( A ,n=8 / g r o u p )a n dp r o t e i n( B ,n=5 / g r o u p )
levels were determined in the spleen at 7 days post-ischemia. Values were expressed as mean ± SEM. * p < 0.05 compared to vehicle (Veh).
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neuroprotection effects may not be caused by a primary
ischemia-reperfusion event but by a secondary event such
as reduced expression of inflammatory mediator in periph-
eral immune cells. The degree of ischemic severity was
comparable between the treatment groups indicated by no
noticeable differences in the degree of cerebral blood flow
reduction during (MFX 83.8 ± 2.3% vs vehicle 83.6 ±
2.0%) and reperfusion 10 min after ischemia (MFX 122.6
± 7.2% vs vehicle 134.7 ± 9.2%) and in MCP-1 mRNA
levels produced in the post-ischemic brain (Figure 4A).
MFX significantly decreased the WBC counts in circula-
tion (2264 ± 259 vs 960 ± 60 cells/μl, n = 7-10, p < 0.01).
Further FACS analysis in the spleen revealed the reduced
percentage of monocyte population in the MFX-treated
group (4.1 ± 1.0% vs 2.9 ± 0.4%, n = 5, p < 0.05). Since ele-
vated systemic inflammation induces monocytosis, the
decreased population of spleen monocytes by MFX treat-
ment indicates attenuation of peripheral inflammation fol-
lowing stroke. Therefore, the protective mechanism may
lie in limiting the expansion of secondary injury associated
with the reduced inflammatory state in monocytes.
In summary, antibacterial MFX treatment after stroke
shifted inflammatory status in the spleen toward a less
inflammatory state and attenuated post-ischemic inflam-
mation and injury. The tight association between MFX-
induced neuroprotection and inflammatory status in the
brain and spleen suggests that reducing peripheral
inflammation may be beneficial in ameliorating post-
ischemic inflammation and injury. The potential influ-
ence of inflammatory status in peripheral monocytes on
CNS injury suggests a possible cell-based strategy to
limit the expansion of secondary injuries during post-
ischemic periods.
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Figure 4 Effect of MFX on post-ischemic inflammation and
injury in the brain. MCP-1 mRNA (A) and CCR2 mRNA (B) levels
were measured in the 7 d post-ischemic brain in vehicle (Veh) and
MFX treated mice. CCR2 mRNA level (B) was decreased by MFX, and
MCP-1 was not significant between Veh and MFX treatment (A). b-
actin was used as internal control and data were normalized with
the contralateral side in Veh group. Values were expressed as
mean ± SEM. Contl, contralateral side; Ipsl, ipsilateral side. ** p <
0.01 and *** p < 0.001 compared to contralateral side; # p <0 . 0 5
compared to Veh; NS, not significant. n = 6-8/group. C, Infarct
volume measurement 7 d after MCAO. Values were present as
mean ± 95% Confidence interval. * p < 0.05 compared to Veh. n
=1 2 - 1 5 / g r o u p .
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